A new study revealed that corticosteroid treatment in patients with chronic obstructive pulmonary disease (COPD) or asthma increases their risk of developing a specific form of lung cancer – squamous cell carcinoma. The study, “The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous…
News
Inova Labs Inc., a company dedicated to medical devices for the treatment of respiratory conditions including chronic obstructive pulmonary disease (COPD), recently received the New Product Award 2015 for its oxygen concentrator system Activox DUO2™. The award was given by HME Business, part of the HME Media Group, which…
LifeMap Solutions recently announced that its free iOS app, COPD Navigator is now available for download on iTunes. An enhanced version branded as SuperCare iBreathe, deployed by SuperCare Health, will also soon be released. LifeMap, a digital-health arm of BioTime, Inc., developed the app in close…
A dossier assessment developed by the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of the fixed-dose combination therapy tiotropium plus olodaterol (Spiolto Respimat), approved this year for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The study compared tiotropium/olodaterol…
The Lung Association in Canada, as part of its Breathing as One research campaign, and Aeri Health, a company from Vancouver specialized in health management, have partnered to launch a novel mobile app for patients with chronic obstructive pulmonary disease (COPD). According to a news release, the app…
Nonin Medical, the developer of the finger pulse oximeter and a leader in designing and manufacturing non-invasive medical monitoring, recently announced a collaboration with Tri-anim Health Services to bring Nonin’s new COPD STEP™ (Seamless Treatment and Exacerbation Prevention) Plan to hospitals in the United States commencing this November. The announcement…
Novartis recently announced that the company’s once-a-day Ultibro® Breezhaler® (indacaterol/glycopyrronium), a dual bronchodilator, has meet its primary endpoint in a Phase 3 clinical trial (FLAME trial), showing superior efficacy when compared to twice-a-day Seretide® (salmeterol/fluticasone) in reducing mild, moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations. The IGNITE Phase…
Sunovion Pharmaceuticals together with the COPD Foundation has launched a novel video series, called Reel COPD, sharing first-hand stories from patients and caregivers. The videos, three of which are already available at COPDTogether.com, provide personal insights into life with a progressive and chronic illness, and are intended to motivate and help guide others dealing with the…
Verona Pharma plc, a United Kingdom-based biopharmaceutical company dedicated to therapies for respiratory disorders, recently announced the completion of the patient enrollment phase in two Phase 2a clinical trials assessing the company’s product RPL554. RPL554 is a “first-in-class” inhaled drug under development for respiratory conditions such as chronic obstructive…
In a recent study entitled “DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease,” researchers propose that cigarette smoke induces damage to telomeres, and that telomere dysfunction promotes lung impairment and decline in chronic obstructive pulmonary disease (COPD) patients. The study was…
Recent Posts
- Injection therapy may cut rate, impact of severe COPD exacerbations
- Waiting on that one-thing-a-day season in my COPD journey to pass
- The second chance we don’t always see with COPD
- My ‘and then add’ method makes meal prep easier with COPD
- Movement isn’t optional with COPD, so I turned to Voltaren to get my steps back